Vectibix®

Generic Name: Panitumumab
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
20020408Treatment of subjects with metastatic colorectal cancer who had disease progression during or after prior standard fluoropyrimidine, irinotecan, and oxaliplatin chemotherapy3

An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects with Metastatic Colorectal Cancer 

20025409Metastatic Colorectal Cancer2A Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination with Irinotecan, Leucovorin, and 5-Fluorouracil in Patients with Metastatic Colorectal Cancer
20030167Treatment of subjects with metastatic colorectal cancer who had disease progression during or after prior standard fluoropyrimidine, irinotecan, and oxaplatin chemotherapy2

A Phase 2, Multicenter, Single-arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and  Oxaliplatin Chemotherapy

20030194Third- or fourth-line monotherapy in subjects with metastatic colorectal cancerNAA Multicenter Open-Label Single Arm Clinical Trial to Determine the Safety of ABX-EGF Extended Therapy in Subjects with Metastatic Colorectal Cancer
20030250Third- or fourth-line monotherapy in subjects with metastatic colorectal cancer whose tumors express low or negative EGFr levels by immunohistochemistry2
A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFr Levels by Immunohistochemistry Following Treatment with Fluoropyrimidine, Irinotecan,and Oxaliplatin Chemotherapy
20030251Advanced Solid Tumors1An Open-label Clinical Trial Evaluating the Safety and Pharmacokinetics of 2 Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
20040192Advanced Solid Tumors1A Phase 1 Clinical Study of ABX-EGF (Panitumumab) Evaluation of the Safety and Pharmacokinetics of ABX-EGF in Japanese Subjects with Advanced Solid Tumors
20040235Subjects with loco-regionally advanced squamous cell carcinoma of the head and neck who are candidates for IC followed by CRT1bAn Open-label, Multi-Center, Dose-finding Study to Evaluate the Safety and Tolerability of AMG 706 or Panitumumab when Administered with Induction Chemotherapy (IC) and/or Chemo-radiotherapy (CRT) in the Treatment of Subjects with Loco-regionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
20040249First-line treatment of metastatic colorectal cancer3B

A Randomized, Open-label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab with and without Panitumumab in the First-line Treatment of Subjects with Metastatic Colorectal Cancer

200501812nd line metastatic colorectal cancer in combination with chemotherapy3A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal Cancer
200502031st line metastatic colorectal cancer in combination with chemotherapy3A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Oxaliplatin/ 5-fluorouracil/ leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ leucovorin Alone in Patients with Previously Untreated Metastatic Colorectal Cancer
20050216Subjects with Metastatic Colorectal Cancer Who Developed Progressive Disease or Relapsed While on or After Prior Fluoropyrimidine, Irinotecan and Oxaliplatin Chemotherapy2A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF (Panitumumab) Monotherapy in Japanese Subjects with Metastatic Colorectal Cancer Who Developed Progressive Disease or Relapsed While on or After Prior Fluoropyrimidine, Irinotecan and Oxaliplatin Chemotherapy.
20050236Cancer of Head and Neck2A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects who Fail the Combination Chemotherapy Only Arm
20050251Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck3A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
20060141Second-line metastatic colorectal cancer (mCRC) wild-type KRAS tumors in combination with chemotherapy.2A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer with Wild-type KRAS tumors
20060277Second-line metastatic colorectal cancer (mCRC)2Multi-center, Open-label, Single-arm Trial Evaluating Panitumumab in Combination with FOLFIRI Therapy Following First-line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer
20060314Metastatic colorectal cancer (mCRC)2A Single-arm Multicenter Phase 2 Study of Panitumumab in Combination with Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer
20060332Subjects with metastatic colorectal cancer (mCRC) with disease progression on or following fluoropyrimidine-, oxaliplatin-, and/or irinotecan-containing chemotherapy regimens1b/2A Phase 1b/2 Trial of AMG 655 in Combination with Panitumumab in Subjects with Metastatic Colorectal Cancer
20060447wild-type KRAS metastatic colorectal cancer1b/2A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination with Panitumumab versus Panitumumab Alone in Subjects with Wild-Type KRAS Metastatic Colorectal Cancer
20060542Unresectable or metastatic adenocarcinoma of the Pancreas2

Phase II, Multi-center, Open-label, Single-Arm Study using Gemcitabine and Panitumumab in the First-line Treatment of Subjects with Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas

20062010Unresectable metastatic colorectal cancer (mCRC) expressing wild-type (wt) KRAS1A Phase I, Open-label Study to Determine the Effect of Panitumumab on the Pharmacokinetics of Irinotecan in Subjects with Unresectable Metastatic Colorectal Cancer
20062079Unresected, locally advanced squamous cell carcinoma of the head and neck2A Phase 2 Randomized Trial of Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
20062080Unresected, locally advanced squamous cell carcinoma of the head and neck2A Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
20062088Squamous Cell Carcinoma of Head and Neck (SCCHN)2Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
20070509Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer2A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
20070820Metastatic colorectal cancer expressing wild type (wt) KRAS and refractory to irinotecan- and oxaliplatin-containing regimens, or refractory to oxaliplatin-containing regimens2Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild-type KRAS and Refractory to Oxaliplatin- or Irinotecan- and Oxaliplatin containing Regimens to Evaluate Mechanisms of Acquired Resistance to Panitumumab
20080008Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck2A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
20080763Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer3A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
20100007Chemorefractory, Wild-type KRAS, Metastatic Colorectal Cancer (mCRC).3Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer
20101120Patients with mCRC treated with VectibixObservational StudyMedical Records Review to Describe the Patterns of KRAS/RAS Testing and Vectibix Use in Europe.